Aarti Pharmalabs Limited

NSE: AARTIPHARM · Healthcare

₹929.10+0.09%06 Nov 2026

Ask the data

Instant answers about Aarti Pharmalabs Limited — computed from its filings, no language model

Market cap₹8,425 cr

Current price₹929.10

High / Low₹975 / ₹592

P/E33.4

P/B3.74

Book value₹248.7

ROE11.2%

ROCE12.1%

Debt / equity0.37

Dividend yield0.43%

EPS (TTM)₹27.85

Face value₹5

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY23	FY24	FY26
Revenue	1,945	1,853	1,819
EBITDA	342	386	369
Operating margin	17.6%	20.8%	20.3%
Interest	21	17	47
Depreciation	63	73	104
Profit before tax	261	300	225
Tax	67	84	58
Net profit	193	216	173
EPS ₹	21.35	23.93	19.27
Operating cash flow	263	216	262
Capex	120	199	409
Dividend paid	0	18	36
Total assets	2,231	2,582	3,482
Equity	1,558	1,757	2,125

Quarterly performance

last 14 quarters · ₹ crore

showing latest 8 of 14 periods

	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	485	458	440	449	506	555	458	538	386	418	432	583	536	610
Operating profit	80	85	88	96	118	96	94	129	95	75	102	113	136	135
Operating margin	16.5%	18.5%	20.0%	21.3%	23.2%	17.4%	20.5%	23.9%	24.7%	17.9%	23.7%	19.4%	25.4%	22.1%
Other income	1	0	1	1	2	2	4	5	2	0	-0	8	0	0
Interest	6	4	4	4	5	5	6	10	7	11	13	17	13	15
Depreciation	16	17	18	19	19	20	21	23	23	25	29	28	30	31
Profit before tax	59	64	67	74	96	74	72	101	67	39	58	76	94	88
Tax	16	17	15	21	30	18	17	27	16	11	15	21	25	24
Net profit	43	51	52	53	64	55	55	74	50	29	46	61	76	69
EPS ₹	4.73	5.20	5.72	5.82	7.20	6.12	6.03	8.16	5.46	3.08	5.29	6.74	8.40	7.88
Revenue YoY	—	—	—	—	4.3%	21.2%	4.1%	19.9%	-30.5%	-8.7%	-19.6%	—	38.7%	45.9%
Profit YoY	—	—	—	—	50.1%	8.8%	5.4%	40.2%	-10.7%	-47.7%	-37.3%	—	53.8%	141.2%

Returns & margins

trailing-twelve-month, per quarter

	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '26	JUN '26	SEP '26
ROE	12.0%	12.5%	12.8%	12.2%	13.4%	8.7%	10.0%	11.2%
ROCE	15.2%	15.7%	16.2%	15.0%	16.5%	10.2%	11.4%	12.1%
Net margin	10.8%	11.9%	11.5%	11.5%	12.1%	10.2%	10.8%	11.7%
EBITDA margin	19.0%	20.8%	20.4%	20.5%	21.2%	21.2%	21.6%	22.5%
Debt / equity	0.12	0.15	0.15	0.20	0.20	0.32	0.32	0.37
Interest coverage	15.26	18.45	18.35	17.15	14.68	6.13	6.04	6.52
Asset turnover	0.79	0.72	0.76	0.71	0.74	0.52	0.57	0.56

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 7 periods

	MAR '23	SEP '23	MAR '24	SEP '24	SEP '25	MAR '26	SEP '26
Share capital	45	45	45	45	45	45	45
Other equity / reserves	1,513	1,612	1,712	1,811	2,001	2,079	2,209
Total equity	1,558	1,658	1,757	1,857	2,046	2,125	2,255
Borrowings	214	204	264	368	589	686	836
Current liabilities	592	559	694	683	811	938	1,179
Non-current liabilities	81	97	131	236	409	420	392
Total assets	2,231	2,313	2,582	2,777	3,266	3,482	3,826
Property, plant & equipment	923	944	1,015	1,094	1,400	1,336	1,466
Capital work-in-progress	62	89	78	116	160	305	308
Investments	74	81	107	94	187	194	204
Inventories	602	603	643	720	621	640	794
Receivables	440	425	519	433	470	583	685
Cash & equivalents	25	25	24	41	32	9	4

Cash flow

annual · ₹ crore · line = free cash flow

	FY23	FY24	FY26
Cash from operations	263	216	262
Cash from investing	-158	-215	-431
Cash from financing	-163	10	171
Capex	120	199	409
Free cash flow	143	18	-147
Dividends paid	0	18	36

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹1,466 cr38%

CWIP

₹308 cr8%

Investments

₹204 cr5%

Inventories

₹794 cr21%

Receivables

₹685 cr18%

Cash & equivalents

₹4 cr0%

Other assets

₹365 cr10%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Aarti Pharmalabs Limited	8,425	929.10	33.4	3.74	11.2%

StoxGud checklist: Bullish setup · 9/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-2.5%

6 months+19.5%

1 year+11.7%

3Y CAGR+32.0%

5Y CAGR—

10Y CAGR—

50-day avg₹877.94

200-day avg₹751.99

RSI (14)59

FAQs

What is the share price of Aarti Pharmalabs Limited?

Aarti Pharmalabs Limited (AARTIPHARM) closed at ₹929.10 on NSE on 06 Nov 2026.

What is the market cap of Aarti Pharmalabs Limited?

₹8,425 crore at the latest close.

What is the P/E ratio of Aarti Pharmalabs Limited?

33.4, on trailing-twelve-month earnings from its filings.

How fast is Aarti Pharmalabs Limited growing?

Aarti Pharmalabs Limited: Latest-quarter revenue is up 45.9% year on year, profit up 141.2%.

How profitable is Aarti Pharmalabs Limited?

On a trailing-twelve-month basis return on equity is 11.2%, return on capital employed 12.1%, operating margin 22.5%, net margin 11.7%.

How much debt does Aarti Pharmalabs Limited have?

Aarti Pharmalabs Limited is lightly geared: debt to equity is 0.37 with borrowings of ₹836 cr against cash of ₹4 cr (balance sheet of 2026-09-30). Operating profit covers interest 6.5 times.

Financials parsed from Aarti Pharmalabs Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '23, annual from FY23, balance sheet from Mar '23. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.